Lasers in surgery and medicine · 2025
Outcomes of Temperature-Controlled Radiofrequency in Treating Vulvar Lichen Sclerosus: A Pilot Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Nengxiu, Li Ying, Lin Chaoqin
Аннотация
OBJECTIVE: This study aimed to evaluate the efficacy and safety of transcutaneous temperature-controlled radiofrequency (TTCRF) in the treatment of female vulvar lichen sclerosus (VLS).
METHODS: A retrospective analysis was conducted on VLS patients treated with TTCRF at our hospital between May 2021 and May 2023. Each patient underwent ten TTCRF sessions, spaced 1 week apart. Complications were monitored throughout the treatment, and efficacy was assessed using the Cattaneo scoring system and the Patient Global Impression of Change (PGI-C) questionnaire at 1 and 6 months Posttreatment.
RESULTS: A total of 40 patients were included in the study, with a mean age of 44.98 ± 11.14 years and a mean BMI of 22.78 ± 2.62 kg/m². Follow-up results at 1 and 6 months Posttreatment showed significant improvements in pruritus degree, skin elasticity, and skin color compared to baseline (p < 0.05), although no significant change in lesion scope was observed. According to the PGI-C questionnaire, 75% (30/40) of patients reported improvement or significant improvement at 1 month Posttreatment, which decreased to 60% (24/40) at 6 months. No adverse reactions were reported during the treatment or follow-up periods.
CONCLUSION: TTCRF is an effective and safe treatment for female VLS, offering significant short-term symptom relief. However, further research is needed to confirm long-term benefits.
METHODS: A retrospective analysis was conducted on VLS patients treated with TTCRF at our hospital between May 2021 and May 2023. Each patient underwent ten TTCRF sessions, spaced 1 week apart. Complications were monitored throughout the treatment, and efficacy was assessed using the Cattaneo scoring system and the Patient Global Impression of Change (PGI-C) questionnaire at 1 and 6 months Posttreatment.
RESULTS: A total of 40 patients were included in the study, with a mean age of 44.98 ± 11.14 years and a mean BMI of 22.78 ± 2.62 kg/m². Follow-up results at 1 and 6 months Posttreatment showed significant improvements in pruritus degree, skin elasticity, and skin color compared to baseline (p < 0.05), although no significant change in lesion scope was observed. According to the PGI-C questionnaire, 75% (30/40) of patients reported improvement or significant improvement at 1 month Posttreatment, which decreased to 60% (24/40) at 6 months. No adverse reactions were reported during the treatment or follow-up periods.
CONCLUSION: TTCRF is an effective and safe treatment for female VLS, offering significant short-term symptom relief. However, further research is needed to confirm long-term benefits.